Could your company benefit from exposure to over ten thousand therapists working with hundreds of thousands of clients? Or could your company benefit from supporting research to determine which evidence-based treatments are most effective and efficient? Please consider becoming a Corporate Sponsor of the EMDR Research Foundation.
The EMDR Research Foundation is dedicated to the promotion of quality, unbiased research in EMDR therapy. We all know how important it is to be able to back up statements with data and reliable information. To date, we have provided more than $365,000 toward this goal. Examples of studies we have funded include: exploration of the effectiveness of EMDR therapy in treating PTSD in military personnel and civilians, patients with cancer, depression, bipolar disorder, addictions, and children exposed to trauma. You can imagine what a difference this can make both in the lives of clients and in the work of therapists who know they are providing effective, efficient, and evidence based treatment. For a complete list of studies which we’ve supported, or to learn more about the EMDR Research Foundation, please consult the rest of our website.
As a company that works with and for our community, we invite you to join us! By becoming an EMDR Research Foundation Corporate Sponsor, you will make an important difference in many lives, and will also have access to thousands of people in the EMDR community.
Wendy Freitag, President
EMDR Research Foundation
For benefits of various levels of Corporate Sponsorship, please click here:
To read our Corporate Sponsorship Donor Policy, please click: Donor Policy
To view a template for our Corporate Sponsorship Agreement, please click: Corporate Sponsorship Agreement
Click on each filename below to download and save it to your computer.
|1 Corporate Sponsorship - Intro and Sponsorship Levels.pdf||2017-10-20|
|2 Corporate Sponsorship Agreement.pdf||2017-10-20|
|3 Corporate Sponsorship - Donor Policy.pdf||2017-08-25|
|4 Corporate Sponsorship - Sponsorship Levels.pdf||2017-10-20|